

# Jordana Kate Schmier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4627853/publications.pdf>

Version: 2024-02-01

97  
papers

6,456  
citations

117625

34  
h-index

64796

79  
g-index

97  
all docs

97  
docs citations

97  
times ranked

7767  
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic Burden of Periprosthetic Joint Infection in the United States. <i>Journal of Arthroplasty</i> , 2012, 27, 61-65.e1.	3.1	1,365
2	Infection Burden for Hip and Knee Arthroplasty in the United States. <i>Journal of Arthroplasty</i> , 2008, 23, 984-991.	3.1	851
3	Future Clinical and Economic Impact of Revision Total Hip and Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2007, 89, 144-151.	3.0	464
4	The Burden of Influenza B: A Structured Literature Review. <i>American Journal of Public Health</i> , 2013, 103, e43-e51.	2.7	281
5	Complications, Mortality, and Costs for Outpatient and Short-Stay Total Knee Arthroplasty Patients in Comparison to Standard-Stay Patients. <i>Journal of Arthroplasty</i> , 2014, 29, 510-515.	3.1	245
6	Mortality Following the Diagnosis of a Vertebral Compression Fracture in the Medicare Population. <i>Journal of Bone and Joint Surgery - Series A</i> , 2008, 90, 1479-1486.	3.0	207
7	Patient recall and recall bias of health state and health status. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 159-163.	1.4	183
8	Primary and Revision Arthroplasty Surgery Caseloads in the United States from 1990 to 2004. <i>Journal of Arthroplasty</i> , 2009, 24, 195-203.	3.1	179
9	Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data. <i>Hypertension</i> , 2006, 47, 1039-1048.	2.7	161
10	Cost of obesity in the workplace. <i>Scandinavian Journal of Work, Environment and Health</i> , 2006, 32, 5-11.	3.4	118
11	The Breathlessness, Cough, and Sputum Scale. <i>Chest</i> , 2003, 124, 2182-2191.	0.8	104
12	The impact of inadequately controlled asthma in urban children on quality of life and productivity. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 98, 245-251.	1.0	104
13	Health Care CBA and CEA from 1991 to 1996: An Updated Bibliography. <i>Medical Care</i> , 1998, 36, MS1-MS9.	2.4	102
14	A Stitch in Time: Improving Public Health Early Warning Systems for Extreme Weather Events. <i>Epidemiologic Reviews</i> , 2005, 27, 115-121.	3.5	87
15	Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System. <i>Clinical Cardiology</i> , 2017, 40, 430-436.	1.8	76
16	EVALUATION OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF ANEMIA AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS. <i>Chest</i> , 2005, 128, 257S.	0.8	74
17	EVALUATION OF COSTS FOR CYSTOID MACULAR EDEMA AMONG PATIENTS AFTER CATARACT SURGERY. <i>Retina</i> , 2007, 27, 621-628.	1.7	74
18	Allergic Rhinitis: A Potential Cause of Increased Asthma Medication Use, Costs, and Morbidity. <i>Journal of Asthma</i> , 2004, 41, 117-126.	1.7	72

#	ARTICLE	IF	CITATIONS
19	IMPACT OF VISUAL IMPAIRMENT ON USE OF CAREGIVING BY INDIVIDUALS WITH AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 1056-1062.	1.7	68
20	Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 92, 201-207.	1.0	65
21	Willingness to Pay for Complete Symptom Relief of Gastroesophageal Reflux Disease. <i>Archives of Internal Medicine</i> , 2002, 162, 1361.	3.8	63
22	The Impact of Asthma on Health-Related Quality of Life. <i>Journal of Asthma</i> , 1998, 35, 585-597.	1.7	61
23	Perioperative outcomes, complications, and costs associated with lumbar spinal fusion in older patients with spinal stenosis and spondylolisthesis. <i>Neurosurgical Focus</i> , 2014, 36, E5.	2.3	60
24	The Economic Implications of Glaucoma. <i>Pharmacoeconomics</i> , 2007, 25, 287-308.	3.3	59
25	Anemia, costs and mortality in chronic obstructive pulmonary disease. <i>Cost Effectiveness and Resource Allocation</i> , 2006, 4, 17.	1.5	53
26	The Complexity of Treatment Adherence in Adults with Asthma: Challenges and Opportunities. <i>Journal of Asthma</i> , 1998, 35, 455-472.	1.7	46
27	The quality of life impact of acute exacerbations of chronic bronchitis (AECB): A literature review. <i>Quality of Life Research</i> , 2005, 14, 329-347.	3.1	46
28	Benefits And Costs Of Immunizing Children Against Influenza At School: An Economic Analysis Based On A Large-Cluster Controlled Clinical Trial. <i>Health Affairs</i> , 2008, 27, w96-w104.	5.2	46
29	Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. <i>Quality of Life Research</i> , 2000, 9, 819-827.	3.1	44
30	Development and validation of a disease-specific treatment satisfaction questionnaire for gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 907-915.	3.7	44
31	Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States. <i>Pharmacoeconomics</i> , 2002, 20, 617-628.	3.3	37
32	Cost savings of reduced constipation rates attributed to increased dietary fiber intakes: a decision-analytic model. <i>BMC Public Health</i> , 2014, 14, 374.	2.9	37
33	Mortality, Cost, and Health Outcomes of Total Knee Arthroplasty in Medicare Patients. <i>Journal of Arthroplasty</i> , 2013, 28, 449-454.	3.1	36
34	Estimated hospital costs associated with preventable health care-associated infections if health care antiseptic products were unavailable. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 197.	1.9	35
35	Time and Economic Cost of Constipation Care in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2002, 3, 215-223.	2.5	34
36	The Burden of Age-Related Macular Degeneration. <i>Pharmacoeconomics</i> , 2006, 24, 319-334.	3.3	34

#	ARTICLE	IF	CITATIONS
37	Impacts of a Smoking Cessation Benefit Among Employed Populations. <i>Journal of Occupational and Environmental Medicine</i> , 2007, 49, 11-21.	1.7	34
38	Trends in Annual Medicare Expenditures for Glaucoma Surgical Procedures From 1997 to 2006. <i>JAMA Ophthalmology</i> , 2009, 127, 900.	2.4	34
39	MEDICARE EXPENDITURES ASSOCIATED WITH DIABETES AND DIABETIC RETINOPATHY. <i>Retina</i> , 2009, 29, 199-206.	1.7	33
40	Cost-Effectiveness Analysis of Treatments for Vertebral Compression Fractures. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 273-284.	2.1	33
41	Evaluation of Medicare Costs of Endophthalmitis among Patients after Cataract Surgery. <i>Ophthalmology</i> , 2007, 114, 1094-1099.	5.2	31
42	Health Economic Evaluation Modeling Shows Potential Health Care Cost Savings with Increased Conformance with Healthy Dietary Patterns among Adults in the United States. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2019, 119, 599-616.	0.8	30
43	Utility Assessments of Opioid Treatment for Chronic Pain. <i>Pain Medicine</i> , 2002, 3, 218-230.	1.9	29
44	Meta-analysis of bacterial resistance to macrolides. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 748-757.	3.0	28
45	Treatment costs of cystoid macular edema among patients following cataract surgery. <i>Clinical Ophthalmology</i> , 2016, 10, 477.	1.8	27
46	Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. <i>Clinical Therapeutics</i> , 2017, 39, 1600-1617.	2.5	27
47	The impact of climate change and aeroallergens on children's health. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 229-237.	2.2	26
48	Practical applications of usability theory to electronic data collection for clinical trials. <i>Contemporary Clinical Trials</i> , 2005, 26, 376-385.	1.8	24
49	National Revision Burden for Lumbar Total Disc Replacement in the United States. <i>Spine</i> , 2010, 35, 690-696.	2.0	24
50	Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2014, 8, 1097.	1.8	24
51	An updated estimate of costs of endophthalmitis following cataract surgery among Medicare patients: 2010&ndash;2014. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2121-2127.	1.8	24
52	Patterns and Costs Associated With Progression of Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2012, 154, 675-681.e1.	3.3	23
53	Comparative cost effectiveness of Coflex&reg; interlaminar stabilization versus instrumented posterolateral lumbar fusion for the treatment of lumbar spinal stenosis and spondylolisthesis. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 125.	1.9	22
54	Mortality, Cost, and Downstream Disease of Total Hip Arthroplasty Patients in the Medicare Population. <i>Journal of Arthroplasty</i> , 2014, 29, 242-246.	3.1	22

#	ARTICLE	IF	CITATIONS
55	Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children. <i>Current Medical Research and Opinion</i> , 2006, 22, 1839-1847.	1.9	21
56	First-year treatment patterns among new initiators of topical prostaglandin analogs. <i>Current Medical Research and Opinion</i> , 2009, 25, 851-858.	1.9	21
57	The Economic Impact of Acute Exacerbations of Chronic Bronchitis in the United States and Canada: A Literature Review. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 353-359.	2.2	19
58	Reduction in Oral Corticosteroid Use with Mometasone Furoate Dry Powder Inhaler Improves Health-Related Quality of Life in Patients with Severe Persistent Asthma. <i>Journal of Asthma</i> , 2003, 40, 383-393.	1.7	18
59	Resource utilization and costs of age-related macular degeneration. <i>Health Care Financing Review</i> , 2006, 27, 37-47.	1.8	18
60	Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD). <i>Disability and Rehabilitation</i> , 2006, 28, 1331-1338.	1.8	17
61	Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2010, 4, 1137.	1.8	16
62	A survey of standards and guidelines for cost-effectiveness analysis in health care*. <i>American Heart Journal</i> , 1999, 137, S53-S61.	2.7	14
63	Validation of the Daily Living Tasks Dependent on Vision (DLTV) Questionnaire in a U.S. Population with Age-Related Macular Degeneration. <i>Ophthalmic Epidemiology</i> , 2006, 13, 137-143.	1.7	14
64	Time and economic cost of constipation care in nursing homes. <i>Journal of the American Medical Directors Association</i> , 2002, 3, 215-23.	2.5	14
65	Cardiovascular Healthcare Cost Savings Associated with Increased Whole Grains Consumption among Adults in the United States. <i>Nutrients</i> , 2020, 12, 2323.	4.1	13
66	Characteristics of respondents with glaucoma and dry eye in a national panel survey. <i>Clinical Ophthalmology</i> , 2009, 3, 645.	1.8	12
67	Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective. <i>Current Medical Research and Opinion</i> , 2007, 23, 2867-2875.	1.9	11
68	Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges. <i>Pharmacoeconomics</i> , 2016, 34, 259-272.	3.3	11
69	A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 35-46.	2.1	11
70	First-year treatment costs among new initiators of topical prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2009, 3, 637.	1.8	10
71	Single food focus dietary guidance: lessons learned from an economic analysis of egg consumption. <i>Cost Effectiveness and Resource Allocation</i> , 2009, 7, 7.	1.5	10
72	Impact of visual impairment on service and device use by individuals with diabetic retinopathy. <i>Disability and Rehabilitation</i> , 2009, 31, 659-665.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Effect of battery longevity on costs and health outcomes associated with cardiac implantable electronic devices: a Markov model-based Monte Carlo simulation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 149-158.	1.3	10
74	Cost Effectiveness of Acute Imipramine Therapy versus Two Imipramine Maintenance Treatment Regimens for Panic Disorder. <i>Pharmacoeconomics</i> , 2000, 18, 383-391.	3.3	9
75	Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e185-e198.	0.4	9
76	Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients. <i>Drugs and Aging</i> , 2005, 22, 717-729.	2.7	8
77	Health Care Costs and Savings Associated with Increased Dairy Consumption among Adults in the United States. <i>Nutrients</i> , 2020, 12, 233.	4.1	8
78	Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. <i>Current Medical Research and Opinion</i> , 2006, 22, 1737-1743.	1.9	7
79	First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. <i>Current Medical Research and Opinion</i> , 2010, 26, 2769-2777.	1.9	6
80	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 1003-1010.	2.1	6
81	Medical Service Encounters and Payments Associated with Topical Adjunctive Therapy Use of Timolol for Glaucoma. <i>Clinical Drug Investigation</i> , 2012, 32, 835-842.	2.2	5
82	Cost Savings of Reduced Constipation Rates Attributed to Increased Dietary Fibre Intakes in Europe: A Decision-Analytic Model. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2015, 5, 14-23.	0.4	5
83	Patient-, Caregiver-, and Eye Care Professional-reported Burden of Geographic Atrophy Secondary to Age-related Macular Degeneration. <i>American Journal of Ophthalmic Clinical Trials</i> , 0, 2, 1.	0.0	4
84	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results. <i>Clinical Ophthalmology</i> , 2010, 4, 437.	1.8	3
85	High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al.] <i>Antimicrob Chemother</i> 2005; 55: 748-757]. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 433-434.	3.0	2
86	Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	2
87	Meta-analysis of bacterial resistance to macrolides providing generalizable results: authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 434-435.	3.0	1
88	Costs and Outcomes of Extended-Release vs. Immediate-Release Clarithromycin for Lower Respiratory Tract Infections. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 217-223.	1.6	1
89	Willingness to pay for relief of gastroesophageal reflux disease. <i>Gastroenterology</i> , 2001, 120, A402.	1.3	0
90	Development and validation of the treatment satisfaction questionnaire for GERD (TSQ-G). <i>Gastroenterology</i> , 2003, 124, A505-A506.	1.3	0

#	ARTICLE	IF	CITATIONS
91			